Is NAD+ approved as a medicine?

No. It holds no marketing authorisation from the MHRA, EMA or FDA.

But NR is sold in shops — doesn't that mean it's approved?

No. Food supplement status assesses safety for consumption, not efficacy, and permits no therapeutic claims.

Why is this category particularly claim-prone?

The ageing literature's vocabulary reads as therapeutic before any claim is made, and it maps onto something universally experienced.

NAD+

NAD+ Regulatory Status

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

NAD+ holds no marketing authorisation as a medicine from the MHRA, EMA or FDA. Some precursors are sold as food supplements in some jurisdictions, which is a different regulatory category with different rules — and neither position permits therapeutic claims.

Key facts

MHRA medicine status: Not authorised
EMA medicine status: Not authorised
FDA drug status: Not approved
Precursors: Food supplement status in some jurisdictions
Supply basis here: Laboratory research only
Highest-risk framing: Ageing and longevity language

The position

No regulator has authorised NAD+ as a medicine. Some precursors — nicotinamide riboside in particular — have food supplement status in certain jurisdictions, which permits sale but not therapeutic claims. Those are separate frameworks, and neither one covers NAD+ supplied as laboratory research material.

Why the supplement route confuses things

Because a compound sold legally in a shop looks approved. It is not. Food supplement frameworks assess safety for consumption; they do not assess efficacy for any purpose and do not permit claims that a product treats or prevents anything. A precursor's supplement status says nothing about NAD+, and nothing about efficacy.

Research material referenced

NAD+ 500mg — third-party HPLC tested

View — £49.99

The claims problem specific to this category

The ageing literature is the most claim-prone body of work on this site. Its vocabulary — decline, restoration, reversal, longevity — reads as therapeutic before any claim is deliberately made, and it maps onto something everyone experiences. That combination makes the boundary easier to cross here than anywhere else in the catalogue.

Where the line sits

Reportable: that tissue NAD+ declines with age, that Covarrubias 2020 identified senescent-cell CD38 activity as a driver, that randomised trials of precursors have measured biomarker and physiological endpoints. Not sayable: that NAD+ slows ageing, restores energy, extends lifespan or affects any condition in any person.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic claims about unregulated products in April 2026. The framework turns on the claim and intended use, not on the compound's chemistry — which means a non-peptide in a peptide catalogue is regulated on exactly the same basis as everything around it.

Extended research context

The NAD+ deep dive

Deep dive: the compound in this catalogue that is not a peptide

NAD+ contains no amino acids and no peptide bonds. It is a dinucleotide - a nicotinamide nucleotide and an adenine nucleotide joined through a pyrophosphate bridge - which is the structural grammar of ATP and of RNA, not of a protein. It sits in a peptide catalogue because it reaches the same buyers, not because it belongs there. Saying so matters practically rather than pedantically: essentially all of the general handling guidance on this site is written for peptides and is the wrong guidance here. There is no sequence to verify, so purity by amino acid analysis is meaningless. There are no deletion sequences, because there is no stepwise coupling to produce them. Net peptide content, the figure that decides how much material a lyophilised peptide vial actually contains, has no analogue at all. Even the instruction that does carry over - dry, cold, dark - protects different chemistry, guarding glycosidic and pyrophosphate bonds rather than peptide bonds and methionine residues.

Deep dive: why the finished molecule is the least deliverable of the three

NAD+ carries two negatively charged phosphates and weighs 663.4 Da, and neither property is compatible with crossing a lipid bilayer. Extracellular NAD+ is also actively consumed: CD38 is an ectoenzyme with its active site facing outward, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive tissue NAD+ decline specifically by raising CD38 activity. Put those together and administered NAD+ is a molecule that cannot get in and is being degraded while it waits. Whatever follows most plausibly runs through its breakdown to smaller nicotinamide-containing species, which cells then take up and rebuild NAD+ from internally - which is to say, through exactly the precursors people otherwise take directly. This is why every substantial randomised trial in the field used nicotinamide riboside at 255.25 Da or nicotinamide mononucleotide at 334.22 Da rather than the coenzyme itself. The naming inverts the pharmacology: the finished molecule sounds like the most direct option and is the least.

Deep dive: good early evidence, and the gap that keeps getting closed rhetorically

The randomised human literature here is better than for most of this catalogue. NADPARK was a randomised phase I trial of nicotinamide riboside in Parkinson disease in Cell Metabolism. Orr and colleagues ran a randomised placebo-controlled study in older adults in GeroScience. Yoshino and colleagues published NMN and muscle insulin sensitivity in Science. These are real trials in real journals. What they measured, largely, is whether the intervention does what it is supposed to biologically - and raising a biomarker is not the same as changing an outcome. The step that gets taken rhetorically is from a decline that is real, through a mechanism that is identified, to a benefit that has not been demonstrated. Each link looks small; the chain is not. Nothing in this field approaches the scale of what settled the incretin questions, where TRIUMPH alone enrolled more than 5,800 participants with hard clinical endpoints.

Research applications

▸Cellular NAD+ metabolism and salvage pathway research
▸Sirtuin, PARP and CD38 enzyme activity studies
▸Redox biochemistry and NAD+/NADH ratio measurement
▸Cellular senescence and ageing biology research
▸Mitochondrial function and metabolic assay work
▸Comparative precursor uptake and conversion studies

Handling checklist

✓Verify against CID 5892, 663.4 Da, C21H27N7O14P2 - not by sequence
✓Do not apply peptide purity or net peptide content logic - neither exists here
✓Store lyophilised, cold, dry and protected from light
✓Prepare solutions fresh; nucleotide bonds hydrolyse readily in water
✓Be aware NAD+ and NADH are separately quantifiable oxidation states
✓Identity is confirmed by mass and chromatography against a reference standard

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Applying peptide handling and purity guidance to NAD+

Fix: It is a dinucleotide with no peptide bonds. Sequence verification, protease concerns, disulfide chemistry and net peptide content are all inapplicable.

✗ Assuming administered NAD+ enters cells intact

Fix: Two negative phosphate charges and 663 Da prevent membrane crossing, and CD38 degrades it extracellularly. Effects most plausibly run through breakdown products.

✗ Reading precursor trial results as evidence for NAD+ itself

Fix: Every substantial randomised trial used NR or NMN. NAD+ has essentially no comparable human literature.

✗ Treating a biomarker increase as a demonstrated benefit

Fix: Raising NAD+-related markers is reasonably supported. Durable clinical outcome data does not exist.

✗ Taking a precursor's food supplement status as evidence of efficacy

Fix: Supplement frameworks assess safety for consumption, not efficacy, and permit no therapeutic claims.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is NAD+ approved as a medicine?: No. It holds no marketing authorisation from the MHRA, EMA or FDA.
But NR is sold in shops — doesn't that mean it's approved?: No. Food supplement status assesses safety for consumption, not efficacy, and permits no therapeutic claims.
Why is this category particularly claim-prone?: The ageing literature's vocabulary reads as therapeutic before any claim is made, and it maps onto something universally experienced.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More NAD+ articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum